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Abstract 
Background Therapeutic blockade of the PD-1/PD-L1 axis has transformed the 
management of non-small cell lung cancer (NSCLC). Clinical trials with pembrolizumab have 
enrolled patients with performance status (PS) 0-1. However, around 18% of NSCLC patients 
have a PS of 2 and the activity and safety of pembrolizumab in these patients is unclear. The 
aim of this trial was to evaluate the safety and efficacy of pembrolizumab in these patients. 
Methods PePS2 is a UK multi-centre, single arm, phase II trial in which NSCLC patients with 
a rigorous ascription of PS2 were treated with pembrolizumab 200mg q3weekly. The trial is 
designed to stratify the treatment evaluation by TPS and line of therapy and co-primary 
outcomes were: i) durable clinical benefit (DCB), defined as the occurrence of complete 
response, partial response or stable disease that continues until at least the second CT scan 
scheduled at 18 weeks; and ii) toxicity (TOX), defined as the occurrence at any time of 
treatment-related dose delay or treatment discontinuation due to adverse event. Analysis 
included all patients who had any pembrolizumab. As well as reporting simple observed 
rates for the co-primary outcomes, DCB and TOX rates are estimated by a model-based 
method for correlated binary outcomes. The most common grade 3-4 adverse events were 
dyspnea (affecting n=9 patients), hyponatremia (n=5) and anorexia (n=4). There were 10 
SAE felt to be related to treatment. PePS2 is now closed to recruitment and we present final 
results of the trial. The trial is registered with ClinicalTrials.gov (NCT02733159), EudraCT 
(2015-002241-55) and ISRCTN (10047797). 
Results 60 patients were evaluable for the co-primary outcomes. The observed rate for DCB 
was 38% (95% CI 21-57%) in first-line patients (n=24) and 36% (95% CI 22-52%) in 
subsequent-line patients (n=36), and it was 22% (95% CI 11-41%) in patients with TPS<1% 
(n=27), 47% (95% CI 25-70%) in TPS 1-49% (n=15) and 53% (95% CI 30-75%) in TPS ≥50% 
(n=15). An increase in DCB rates with TPS was also demonstrated in model-based estimates. 
TOX was observed in 28% (95% CI 19-41%) of patients, 18% due to dose delay and 10% due 
to drug discontinuation. There were no G5 treatment-related adverse events and no early 
deaths attributed to hyperprogression.  
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Conclusions NSCLC patients of PS2 are a group of patients of unmet therapeutic need. The 
PePS2 trial shows that pembrolizumab can be safely administered to PS2 lung cancer 
patients, with no increase in the risk of immune-related or other toxicities. Efficacy outcomes 
are at least as good as those in PS0-1 patients and the data provides clinicians with the 
confidence to incorporate pembrolizumab into the treatment pathway of PS2 NSCLC 
patients. 
This trial was funded by Merck, Sharp and Dohme. 
Research in context 
 
Evidence before this study Pembrolizumab, the anti-PD1 monoclonal antibody, is indicated 
as monotherapy in the UK in patients with NSCLC as a first line therapy in those with a tissue 
proportion score (TPS) of >50% and in subsequent lines of therapy in those with TPS > 1%. 
The studies that led to these approvals, which have revolutionised the management of 
NSCLC, only enrolled patients with ECOG performance status of 0-1. Indeed all randomised 
and registration studies of checkpoint blockade agents in NSCLC have also restricted 
inclusion to those of good PS. However, a significant proportion of NSCLC patients in practice 
are PS2. These are patients ambulatory and capable of self-care but unable to carry out any 
work activities and are up and about more than 50% of the time. In the 2018 UK National 
Lung Cancer Audit Annual Report, 6361 of 39199 (18%) patients were PS2. Data on the 
efficacy and safety of checkpoint blockade in this important cohort is very limited, whilst 
outcomes stratified by TPS are negligible. This data is crucial to evaluating the risk:benefit 
equation for these important therapies in this group of patients with significant unmet 
therapeutic need. 
Added value of this study The objective of the PePS2 trial was to answer whether 
pembrolizumab is a beneficial treatment option in advanced PS2 NSCLC patients. A highly 
accurate ascription of PS2 status was crucial. Assessment of PS was performed two weeks 
apart to ensure stability of PS and consistency of assessment, and the ECOG definitions of 
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PS2 status were included in both the inclusion and exclusion criteria and incorporated into 
the eligibility checklist for registration. Durable clinical benefit (no evidence of progression 
at 18 weeks, the time of the 2nd CT evaluation), was a co-primary outcome measure and the 
observed rate was 38% (95% CI 21-57%) in first -line patients (n=24) and 36% (95% CI 22-
52%) in subsequent-line patients (n=36). DCB rate was 22% (95% CI 11-41%) in patients 
with TPS<1%, 47% (95% CI 25-70%) with TPS 1-49% and 53% (95% CI 30-75%) with TPS 
>50%. Toxicity, the second co-primary outcome measure, defined as the occurrence at any 
time of treatment-related dose delay or treatment discontinuation due to adverse event was 
observed in 28% (95% CI 19-41%) of patients, 18% due to dose delay and 10% due to drug 
discontinuation. There were no G5 treatment-related adverse events and no early deaths 
attributed to hyperprogression. Objective response rates were 11% (95% CI 4-28%), 33% 
(95% CI 15-58%) and 47% (95% CI 25-70%) for TPS<1%, TPS1-49% and TPS>50% 
respectively. These data demonstrate that pembrolizumab can be safely administered to PS2 
lung cancer patients, with no obvious increase in the risk of immune related or other 
toxicities or of the risk of hyper-progression. Efficacy outcomes are at least comparable to 
those obtained in PS0/1 patients treated with 2nd line pembrolizumab. 
Implications of all the available evidence These data suggest that pembrolizumab can be 
considered as a treatment option for advanced PS2 NSCLC patients It provides clinicians with 
the evidence base to support the incorporation of pembrolizumab into the treatment 
pathway of PS2 NSCLC patients.  
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Introduction 
The introduction of checkpoint blockade into the management of non-small cell lung cancer 
(NSCLC) has been transformative. Pembrolizumab monotherapy is standard of care in the 
UK for the management of 1st line patients with a tumour proportion score (TPS) ≥50% 
based on superior overall survival (OS) when compared with platinum-containing doublet 
chemotherapy (1) and also for 2nd line patients with TPS ≥1%. Recent updated data from 
the phase I KEYNOTE-001 study of pembrolizumab monotherapy in NSCLC patients 
demonstrated a median OS for previously treated patients of 10.5 months and 5 year OS rate 
of 15.5%: the 5 year OS rate in patients with PD-L1 TPS≥50% was 25% and for those with 
TPS 1-49% it was 12.6% (2). Objective response rate in previously treated patients was 
22.9%, and disease control rate 58.6%. It is also approved for use in combination with 
chemotherapy as a 1st line therapy in both non-squamous NSCLC and squamous cell lung 
cancer patients irrespective of PD-L1 TPS (3, 4). However, these studies and indeed all 
randomised studies have only included patients of performance status (PS) 0-1. A sizable 
proportion of NSCLC patients in real-world clinical practice are PS2. These are patients who 
are ambulatory and capable of self-care but are unable to carry out any work activities and 
are up and about more than 50% of the time (5). In the 2018 UK National Lung Cancer Audit 
Annual Report, the most comprehensive annual analysis of the management and outcome of 
lung cancer patients globally, 6361 of 39199 (18%) patients were PS2 (datasheet available 
at https://www.rcplondon.ac.uk/projects/national-lung-cancer-audit.) Data on the efficacy 
and safety of checkpoint blockade in this important cohort is very limited, whilst outcomes 
stratified by TPS are negligible. A recent Journal of Clinical Oncology commentary specifically 
drew attention to the lack of robust data on the efficacy and safety of checkpoint blockade in 
PS2 NSCLC patients (6). Whilst the FDA and EMA approvals are irrespective of PS, it was 
pointed out that it is unknown whether the available PS0/1 data can be extrapolated to those 
with PS2 or greater disease and clinicians are simply not in a position to adequately assess 
the risk-benefit equation for the use of pembrolizumab in their patients with PS2. Indeed, in 
the UK NHS funding for pembrolizumab is only available for patients with PS 0-1 on the basis 
that this is the only group for which prospective data on activity and safety are available. 
Prospective data are thus necessary to assess whether pembrolizumab monotherapy is a 
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suitable treatment for these patients. We report here the final results of the first prospective 
trial of the outcome of PD-1/PD-L1 blockade enrolling exclusively PS2 NSCLC patients, with 
a rigorous ascription of PS2 status and stratified by TPS. The aim of this study was to examine 
whether pembrolizumab is a beneficial treatment option in advanced PS2 NSCLC patients.  
Methods 
Study design 
PePS2 is a multi-centre, single arm phase II clinical trial of pembrolizumab in advanced 
NSCLC patients with Eastern Cooperative Oncology Group (ECOG) performance status of 2 
(PS2), recruiting from 10 hospitals in the United Kingdom. The trial is designed to stratify 
the treatment evaluation by TPS (<1%, 1-49%, ≥5Ͳ%) and line of therapy (first or 
subsequent). Ethics approval for the trial protocol (ultimately Version 6.0, dated 10-Jul-
2018, Supplementary Material) was obtained from the West Midlands-Edgbaston Research 
Ethics Committee in accordance with national regulatory requirements.  
Participants Participants had histologically confirmed NSCLC, aged ≥ͳͺ years, with a life expectancy of 
>12 weeks and had completed all lines of standard of care therapy that the oncologist 
deemed appropriate. The inclusion and exclusion criteria explicitly included the wording of 
the ECOG definitions of PS2 status and these were also incorporated into the eligibility 
checklist for registration. The trials unit stressed the importance of correct ascription of PS 
at each of the 10 site initiation visits and at monitoring visits the source data was checked to 
ensure participants were assessed as PS2 at time of registration. PS was assessed by the 
treating physician and PS2 status had to be stable for at least two weeks prior to trial entry. 
No molecular testing was required except PD-L1 status, and thus no specific molecular sub-
type of NSCLC such as EGFR mutant or STK11/KRAS double mutations were excluded. 
Patients were eligible regardless of TPS on the archival specimen. PD-L1 testing was only 
performed in laboratories approved by Merck Sharp & Dohme for PD-L1 testing using the 
22C3 antibody. If the TPS could not be assessed on the sample, a repeat biopsy was 
mandatory. However, if TPS could not be ascertained on this repeat biopsy the patient could 
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be included in the trial. Patients were not allowed to have received immunosuppressive 
therapy within seven days prior to first dose and were excluded if there was any evidence of 
clinical autoimmunity or active autoimmune disease that required systemic treatment in the 
previous 2 years. Other key eligibility criteria include measurable disease according to 
RECIST1.1, adequate haematological, hepatic and renal function and being able to give 
written informed consent. Patients with untreated symptomatic brain or leptomeningeal 
metastatic disease were excluded. Patient registration into the trial by the treating clinician 
was by telephone to the central registration service at the Cancer Research UK Clinical Trials 
Unit at the University of Birmingham. 
Procedures 
Pembrolizumab (Merck, New Jersey, United States of America) was administered as a 30-
minute intravenous infusion at a flat dose of 200mg every three weeks, defining a cycle of 
treatment, for up to 2 years or until disease progression. Dose adjustments and cycle delays 
were permitted in the event of toxicity with protocol-specific recommendations. Pre-
treatment evaluation included medical history, clinical examination, laboratory analyses and 
tumour assessment by CT scan with measurable lesions being a requirement for the trial. 
Clinical evaluation and patient-reported quality of life assessment was scheduled every 3 
weeks during treatment in accordance with outpatient clinic visits. CT assessments were 
scheduled to be performed every nine weeks and response was assessed by RECIST v1.1 (7). 
After discontinuation of treatment, patients were followed up every 4 weeks for 6 months 
and every 12 weeks thereafter.  
Outcomes 
The co-primary outcomes for the trial are: i) durable clinical benefit (DCB), defined as the 
occurrence of any one of investigator-reported confirmed complete response (CR), partial 
response (PR) or stable disease (SD) that continues until at least the second CT scan 
scheduled to occur at 18 weeks; and ii) toxicity (TOX), defined as the occurrence at any time 
of a treatment-related dose delay or treatment discontinuation due to an adverse event.   
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Patients with advanced NSCLC who are PS2 have a poor prognosis, especially at the point 
when they fail first line therapy, and therefore DCB at 18 weeks was chosen as this 
represents a meaningful benefit in such patients. Given the use of six month DCB rates in 
many studies enrolling PS0/1 participants, a post-hoc sensitivity analysis was also included 
using a longer-term outcome measure of the occurrence of DCB (specifically at the time of 
the 3rd scan scheduled at 27 weeks, DCB27). TOX was chosen to reflect the feasibility of 
delivering pembrolizumab to this less fit group of patients and reflects the concerns that 
patients express in real-world clinical practice concerning delays in treatment adversely 
impacting on outcome. However, given that there is no robust clinical evidence that delays 
have a significant negative impact on outcome with checkpoint blockade, we have also done 
a post-hoc sensitivity analysis using a toxicity definition that only includes discontinuations 
due to treatment-related toxicity (TOXDIS) and also a more traditional definition that 
includes the incidence of treatment-related grade3-5 adverse events at any time during the 
trial (TOXAE3-5) 
Secondary outcomes include the occurrence of an objective response (OR), i.e. CR or PR as 
the best response recorded over the period of assessment. For those patients whose best 
response is OR, duration of objective response (DOR) from commencement of trial treatment 
will be reported and similarly duration of stable disease (DSD) for those whose best response 
is SD. Also time to progression (TTP), progression-free survival time (PFS) and overall 
survival time (OS) from commencement of trial treatment are included, with patients not 
experiencing the event censored at date last known to be free of the event. In addition, 
patient-reported health-related quality of life (HRQoL) was collected using the FACT-L (8) 
and EQ-5D-5L (9) questionnaires. Questionnaires were administered by research staff and 
completed by patients in clinic at the start of each cycle and generated scores for physical, 
functional, emotional and social well-being together with general health from the former and 
a score measuring the utility of their health state and visual analogue score (VAS) measuring 
general health from the latter.  
Collection and reporting of adverse events (AEs) and serious adverse events (SAEs) was 
mandated throughout the trial in accordance with the Medicines for Human Use and Clinical 
Trials Regulation 2004 and its subsequent amendments. All medical occurrences that met 
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the protocol definition of an AE or SAE were reported using Common Terminology Criteria 
for Adverse Events (CTCAE) version 4.0.  Selected non-serious AEs and SAEs were specified 
in the protocol as Events of Clinical Interest (ECI) and included immune-mediated AEs.  
Statistical analysis 
For the co-primary outcomes, DCB and TOX rates are simultaneously estimated using linked 
logistic regression models (10, 11). The model for DCB incorporates categorical covariates 
for TPS (<1%, 1-49%, ≥ 5Ͳ%) and line of therapy (first or subsequent) to allow efficacy 
estimates to vary between the 6 cohorts. No covariates are included in the model for TOX, 
thereby assuming uniform toxicity rate across all cohorts. A Bayesian approach with 
minimally informative priors was used for model estimation with median and 95% credible 
intervals from the posterior probability distributions providing estimates of the true DCB 
and TOX rates. Full details of the statistical methodology are provided in the Supplementary 
Material. Non-model-based estimates for DCB and TOX rates are also provided with 95% confidence intervals using Wilson’s method. 
There was a strong motivation to deliver findings from the trial quickly due to the patient 
population being a group of significant unmet therapeutic need, so the sample size was 
selected as 60 evaluable patients based on the feasible number to recruit within one year. In 
order to evaluate how well the statistical design would operate with this number of patients, 
the design specified Bayesian decision criteria that might inform decision-making at the final 
analysis. Clinically relevant critical cut-offs for positive decision-making were specified as 
>10% for DCB rate and <30% for TOX rate. Operating characteristics for the trial design were 
based on guidelines that the treatment would be considered successful if p(True DCB rate > 
10%) > 0.7 and p(True TOX rate < 30%) > 0.9. Operating performance of the proposed 
model-based analysis at this sample size was investigated (10, 12) and shown to be 
acceptable, equivalent to approximately 90% power when true DCB rate is 30% and TOX 
rate is 10%, and 2.5% type I error when true DCB rate is 10% and TOX rate is 30%.  
For secondary outcome measures DOR, DSD, TTP, PFS and OS, Kapan-Meier curves are used 
to describe the data and estimate medians with 95% confidence intervals. OR is reported as 
a rate with 95% confidence intervals calculated using Wilson’s method. HRQoL outcomes are 
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reported using means over time. The population for all analyses of efficacy and safety 
includes all patients that received at least one cycle of treatment i.e. one infusion of 
pembrolizumab. There were three patients that had missing TPS categorisation. This 
variable has three levels (<1%, 1-49%, ≥ 5Ͳ%), meaning there were 33 = 27 possible 
imputations. This missing data was handled in model-based analyses by using likelihood-
weighted pooling of the inferences from all 27 imputations (full details are provided in the 
Supplementary Material). All statistical analysis was carried out in R version 3.5.2 (13) using 
rstan version 2.18.2 (14) and the tidyverse (15) suite of packages. Plots were produced using 
ggplot2 (16) and tidybayes (17). 
All presented analyses were conducted in accordance with the trial protocol and the 
supplementary statistical analysis plan. The protocol details analyses of data from the FACT-
L questionnaire that are not presented here. Analyses of all other outcomes are presented 
here, including health-related quality of life outcomes from the EQ-5D-5L questionnaire. 
Post-hoc analyses of the DCB27, TOXDIS, and TOXAE3-5 outcomes are included as described above, in response to reviewers’ comments. 
An independent Trial Steering Committee provided oversight of the trial on behalf of the 
sponsor and reviewed interim data at least once per year during recruitment to ensure 
patient safety. There were no formal stopping rules. The trial is registered with 
ClinicalTrials.gov (NCT02733159), EudraCT (2015-002241-55) and ISRCTN (10047797). 
Role of the funding source 
The funder of the study had no role in study design, data collection, data analysis, data 
interpretation, or writing of the report. The corresponding author had full access to all the 
data in the study and had final responsibility for the decision to submit for publication. 
Results 
Between 4th January 2017 and 13th February 2018, the trial recruited 62 patients from 10 
centres in the United Kingdom, 60 of whom received pembrolizumab and are evaluable for 
co-primary and secondary outcomes (Figure 1). We present here data collected to 8th March 
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2019 at which point the median follow-up was 10 months. Baseline characteristics of the 
study population are shown in Table 1. Median age was 72 years. 24 of the 60 patients (40%) 
received pembrolizumab in the trial as first-line therapy and 45% were PD-L1 negative 
(TPS<1%). The most common Charlson comorbidity index scores were 8 – 10, with 0 being 
comorbidity-free and the theoretical maximum comorbidity score being 37. In terms of 
baseline HRQOL, the mean EQ-5D-5L VAS score at baseline was 53%. Patients received a 
median of 4.5 (inter-quartile range 2 - 12.75) cycles of treatment, with one patient staying 
on treatment for 33 cycles (Figure 1).  
The primary efficacy outcome, DCB, was observed in 22 patients (37%, 95% CI 26-49%) 
across all 3 levels of TPS and both lines of therapy (Table 2). The DCB rate was 38% (95% CI 
21-57%) in first-line pembrolizumab therapy patients and 36% (95% CI 22-52%) in those 
receiving it as a subsequent line of therapy. DCB rates increased with level of TPS, both in 
the observed rates (Table 2), with 22% (95% CI 11-41%) in TPS<1% compared to 53% (95% 
CI 30-75%) in those with TPS≥50%, and in the model-based rates stratified by line of therapy 
(Figure 2). Bayesian estimates of DCB rates from the model gave greater than the pre-
specified 70% probability that the true DCB rate is > 10% in each of the six cohorts (actually 
all greater than 84%). Underpinning DCB is the change from baseline in sum of longest 
diameters of target lesions, which shows that the benefit of pembrolizumab is more 
pronounced as the TPS level increases (Figure 3A and B). Post-hoc sensitivity analysis using 
DCB27 demonstrated that the trial remained positive for this longer term outcome, with an 
observed rate of 32% (see Supplementary Material for details). 
The primary toxicity outcome, TOX, was observed in 17 patients (28%, 95% CI 19-41%) 
(Table 2). The TOX rate in first-line patients was 29% (95% CI 15-49%) and in subsequent-
line patients was 28% (95% CI 16-44%). The model estimated the TOX rate as 28% (95% 
credible interval 17.4% - 39.5%) with 67% probability that the true TOX rate is <30% and, 
in relation to pre-specified benchmarks, we can be 90% certain that it is <35.2%. In those 
that experienced TOX, 11 were due to dose delay, 4 due to drug discontinuation and 2 
experienced both, with median time to first event of 2.6 months. There were 25 events (in 
those 17 patients) associated with the primary toxicity outcome measure, including 
respiratory and thoracic disorders (n=5, one each of cough, dyspnea, hypoxia, pleural 
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effusion, and pneumonitis); laboratory investigations (n=5, one each of increased alanine 
aminotransferase, aspartate aminotransferase, blood bilirubin, and creatinine; one low 
cortisol); and gastrointestinal disorders (n=5, two mucositis and one each of constipation, 
diarrhea, and vomiting). Twenty of these events resolved, 13 with no sequelae. Of the twenty 
events that related to treatment delays (2 in combination with discontinuations), the median 
length of delay was 8 days (range, 1-90). The 7 TOX events associated with discontinuation 
(2 in combination with delays) occurred in six patients. One patient experienced G4 pleural 
effusion and G3 hypoxia. They died the following day with type II respiratory failure, 
advanced chronic obstructive pulmonary disease and lung cancer cited as the reasons for 
death, with no reports of pneumonitis. Another patient discontinued with G1 renal 
dysfunction. They subsequently developed G3 hepatotoxicity which was felt to be possibly 
related to pembrolizumab but that subsequently resolved without sequelae. Further TOX 
events associated with discontinuation were G3 hyponatremia, G3 arthralgia, G2 low 
cortisol, G2 mucositis.  Post-hoc sensitivity analysis using a less stringent toxicity outcome 
that only included discontinuations and not delays (TOXDIS) and a more traditional toxicity 
outcome, treatment-related grade3-5 adverse events at any time during the trial (TOXAE3-
5), demonstrated observed rates of 10% and 15% respectively and probabilities greater than 
90% that the rates are less than 30% (see Supplementary Material for more detail).  
The OR rate was 31% (95% CI 18-47%) in patients who had received previous therapy and 
21% (95% CI 9-40%) in those receiving pembrolizumab first line (Table 2). 2nd line 
pembrolizumab monotherapy is licensed for patients with TPS ≥ ͳ% and in first-line patients 
with TPS ≥50%: the trial estimated OR rate was 33% (95% CI 15-58%) in those with TPS 1-
49% and 47% (95% CI 25-70%) in those with TPS ≥ 5Ͳ% (Table 2). The relationship 
between TPS and response is further elucidated by Figures 3A and B. Median DOR, DSD and 
TTP were 14.6 months (95% CI 12.1 – NR), 4.4 months (95% CI 4.0 – 13.8) and 11.9 months 
(95% CI 4.0 – NR) respectively (Supplementary Figures 1 and 2). Median DOR in first-line 
patients was 12.6 months (95% CI 11.4 – NR) and in subsequent-line patients it was 14.6 
months (95% CI 12.1 – NR). Median PFS and OS were 4.4 months (95% CI, 3.3 - 9.9) and 9.8 
months (95% CI, 7.1 - 14.6) respectively (Table 2 and Figure 4) and both markedly improve 
with increasing TPS (Table 2 and Supplementary Figures 3 and 5). Median PFS was 4.3 
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months (95% CI 1.9 – 13.1) in first-line patients and 4.4 months (95% CI 3.3 – 11.9) in 
subsequent-line patients (Table 2 and Supplementary Figures 4 and 6). 
We recorded 704 adverse events (AEs) in 58 different patients. Figure 5 shows the per-
patient incidence of all immune-related AEs and non-immune-related events occurring in at 
least 10% of patients. Rash and hypothyroidism were the most common immune-related 
events. Grade 3-5 AEs occurred in 44 (73%, 95% CI 60-83%) patients. Twelve Grade 3-5 AEs 
classified as at least possibly related to pembrolizumab occurred in 9 (15%, 95% CI 8-26%) 
patients. In addition to the TOX events described above, these included urinary tract 
infection, dehydration, and myalgia. There were no treatment-related G5 AEs reported and 
no early deaths that were attributed to hyperprogression, based on a widely-used definition 
(18). 
Patient-reported outcomes of quality of life show that for those patients remaining on 
treatment and alive and well enough to complete questionnaires, their scores across all 
timepoints on average are better than baseline (Figure 6). The mean EQ-5D-5L VAS was 0.71 
(SE=0.21) for patients after one year of therapy compared to 0.53 (SE=0.09) for all patients 
at baseline. Similar profiles are seen in first-line and subsequent-line patients (data not 
shown). 
Discussion 
In real world practice PS2 NSCLC patients constitute a significantly-sized patient group with 
unmet therapeutic need. The PePS2 trial is the first ever trial to prospectively investigate the 
effect of checkpoint blockade in NSCLC patients with PS2 across all histologies including the 
most prevalent sub-type adenocarcinoma. The CHECKMATE171 trial of nivolumab therapy, 
which has been published in abstract form (19), prospectively enrolled PS0, 1 and 2 patients 
and reported PS2 outcomes separately. However, this study was only for patients with 
squamous cell lung cancer, did not collect PFS or DCB data and did not analyse outcome by 
TPS.  Crucial to the conduct of the current study was a highly accurate ascription of PS2 status 
and minimisation of the possibility of downgrading patients with PS1 status to allow them 
to enter the trial. We mitigated against this by assessment of PS two weeks apart to ensure 
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stability of performance status and consistency of its assessment, and by including the ECOG 
definitions of PS2 status explicitly in both the inclusion and exclusion criteria and their 
incorporation into the eligibility checklist for registration. Physicians rather than patients 
assessed PS. There is good agreement between nurse and oncologist assessment of PS in 
patients with lung cancer (20) but patients tend to rate themselves of lower PS than 
physicians (20-21). Whilst there are clear differences in survival by PS strata determined by 
physicians, survival curves of patient assessed PS1 and PS2 are superimposed (6). Cox 
models including physician-assessed PS best fitted the observed survival. In comparing 
patient versus physician assessment of whether they would be eligible for a clinical trial 
requiring PS 0 or 1, the study showed that in 24/30 cases of disagreement, the patient would 
have excluded themselves and yet these 24 patients had a median OS of 8.7 months which 
was numerically higher than the entire patient assessed PS1 cohort (20). We were extremely 
keen to minimise any tendency to downgrade a true PS1 patient to PS2 and these data 
strongly suggest that this tendency is minimised when relying on physician assessment of 
PS rather than patient assessed PS, thereby justifying our choice in the PePS2 trial. Finally, 
we have compared the EQ5D VAS score at baseline for patients in our trial against patients 
in KEYNOTE-010 (22): our PS2 patients had considerably worse quality-of-life score of 53% 
compared to the PS0-1 patients of 69.8%. 
We demonstrate that pembrolizumab can be safely administered to PS2 lung cancer patients, 
with no obvious increase in the risk of immune related or other toxicities or of the risk of 
hyper-progression. Efficacy outcomes are at least comparable to those obtained in PS0/1 
patients treated with 2nd line pembrolizumab (23). In the large KEYNOTE-001 single arm 
study enrolling PS0/1 patients the ORR was 18%, mPFS was 3 months and median OS 9.3 
months in previously treated patients. Equivalent efficacy outcomes in the previously 
treated PS2 patients treated in the current study were ORR 31%, mPFS 4.4 months and mOS 
10.4 months. In KEYNOTE-001, the response rate was 24.8% in previously untreated 
patients, compared to 21% in our first-line PS2 cohort, and mPFS was 6 months, compared 
to 4.3 months in the current study.  
Pembrolizumab is currently licensed in the UK for previously treated patients with PD-L1 
TPS > 1% and in first line patients with TPS ≥50%: response rates were 33% (95% CI 15-
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58%) in those with PD-L1 TPS 1-49% and 47% (95% CI 25-70%) with PD-L1 TPS ≥50%. In 
the KEYNOTE-001 study equivalent response rates were 16.5% and 45.2%. In the TPS≥50% 
group herein mPFS was 12.6 months, double that figure at 6.3 months in the KEYNOTE-001 
study. Although, cross trial comparisons lack robust statistical validity there is evidence that 
PS2 patients treated with pembrolizumab are obtaining at least as useful outcomes as their 
PS0/1 counterparts.  
Currently in the UK, for example, PS2 NSCLC patients without a targetable aberration are 
offered carboplatin-based chemotherapy as a first-line option. In the first study to compare 
single agent chemotherapy with doublet chemotherapy in PS2 advanced NSCLC patients, the 
mOS with pemetrexed/carboplatin was 9.3/12 months (24). The updated OS data from 
KEYNOTE-024 enrolling PS0/1 with TPS ≥50% patients demonstrate a median OS of 14.2/12 
months for platinum-containing doublet chemotherapy and median OS for pembrolizumab 
of 30 months (25). Our data provide safety and efficacy evidence that PS2 TPS ≥50% could 
be considered for first line pembrolizumab monotherapy In the 2nd line setting the only 
standard systemic anti-cancer therapy option for PS2 patients is docetaxel but this is usually 
very poorly tolerated in this patient population and very few PS2 patients would be 
submitted to this therapy. Our data also provides evidence to support the use of 
pembrolizumab monotherapy as a valuable and well tolerated second line treatment option 
in PS2 patients, many of whom previously were not offered 2nd line therapy. 
In summary, these data suggest that pembrolizumab can now be considered as a treatment 
option for advanced PS2 NSCLC patients in the first-line and subsequent-line settings. This 
study supports the incorporation of pembrolizumab into the treatment pathway of PS2 
NSCLC patients. It also supports the investigation of checkpoint blockade in patients with 
performance status worse than 0-1 in multiple other cancers where these treatments are 
active, clearly a significant number of patients. 
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Table 1: Baseline characteristics 
 Study Population  
(n=60) 
Sex  
   Male  33 (55%) 
   Female 27 (45%) 
Age (years)  
   Median (Interquartile range) 72 (65-75) 
Histology  
   Adenocarcinoma 41 (68%) 
   Squamous Cell Carcinoma 12 (20%) 
   Other 7 (12%) 
PD-L1 TPS  
   < 1% 27 (45%) 
   1 - 49% 15 (25%) 
   50  - 100% 15 (25%) 
   Unknown 3 (5%) 
Line of Therapy  
   Firsta 24 (40%) 
   Subsequent 36 (60%) 
CT delivered as part of curative-intent treatment 
completed <12 months previous 
 
1 
1 previous line of CT for advanced disease 
o platinum-containing 
o non-platinum-containing 
 
25 
1 
2 previous lines of CT for advanced disease 7 ≥ʹ previous lines including targeted treatment 2 
Smoking status   
   Current smoker 11 (18%) 
   Ex-smoker 43 (72%) 
   Never smoked 3 (5%) 
   Not Reported 3 (5%) 
Pack-years  
   Median (IQR) 40 (26-57.5) 
Charlson Comorbidity Index  
   0 – 7 21 (35%) 
   8 – 10 33 (55%) 
   11 – 12 6 (10%) 
a includes 8 patients who were reported to have had previous chemotherapy as part of 
curative-intent treatment delivered >12 months previous  
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Table 2: Co-primary and key secondary outcome measures - summary statistics with 
95% confidence intervals (CI), for all patients and stratified by line of therapy and TPS  
 
 DCB rate (n) 
95% CI 
TOX rate (n) 
95% CI 
OR rate (n) 
95% CI 
Median PFS 
(months) 
95% CI 
Median OS 
(months)  
95% CI 
All (n=60) 37% (22) 
26 – 49% 28% (17) 19 – 41% 27% (16) 17 – 39% 4.4  3.3 - 9.9 9.8 7.1 - 14.6 
      
Line of 
therapy 
     
First-line 
(n=24) 
38% (9) 
21 – 57% 29% (7) 15 – 49% 21% (5) 9 – 40% 4.3 1.9 – 13.1 7.9 2.6 - NR 
Subsequent-
line (n=36) 
36% (13) 
22– 52% 28% (10) 16– 44% 31% (11) 18 – 47% 4.4 3.3 - 11.9 10.4 8.1 - 16.6 
      
PD-L1 TPS      
<1% (n=27) 22% (6) 
11 – 41% 26% (7) 13 – 45% 11% (3) 4 – 28% 3.7  2.1- 6.0 8.1  4.5 - 13.0 
1-49% (n=15) 47% (7) 
25 – 70% 13% (2) 4 – 38% 33% (5) 15 – 58% 8.3  3.5 - NR 12.6  7.9 - NR ≥ 5Ͳ% ȋn=ͳ5Ȍ 53% (8) 
30 – 75% 40% (6) 20 – 64% 47% (7) 25 – 70% 12.6 1.9 - NR 14.6 4.6 - NR 
Unknown 
(n=3) 
NE (1) NE (2) NE (1) NE NE 
NR –upper level of 95% confidence intervals not reached with current level of follow-up 
NE – summary statistic not estimated because number of patients in category too small to 
be meaningful 
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Figure 1: Trial profile 
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Figure 2: Primary efficacy outcome measure - DCB rates and bands for 50%, 80% and 
95% credible intervals for each cohort estimated from model 
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Figure 3: (A) Change from baseline in the sum of the longest diameters of the baseline-specified 
target lesions for patients with and without DCB. Horizontal guides show the RECIST PR and 
PD thresholds. 15 patients are not shown because they had no post-baseline CT scan, and 3 
patients are not shown because they have unknown TPS. (B) Best change from baseline in the 
sum of the longest diameters of the baseline-specified target lesions. 15 patients with no post-
baseline CT scan are shown with best change of +100%. 
(A) 
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Figure 4: Progression-free survival (A) and overall survival (B) (tick marks represent 
censored times) 
See Supplementary Material for PFS and OS curves split by TPS and line of therapy 
(A) 
 
 
 
 
 
 
 
 
 
 
 
 
(B) 
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Figure 5: Incidence of adverse events grouped into potentially immune-related and 
non-immune-related  
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Figure 6: Mean HRQoL scores over time whilst patients were on trial treatment, for 
periods with at least 10 observations 
 
 
